Fred Aslan Sells 23,429 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total transaction of $255,844.68. Following the completion of the transaction, the chief executive officer directly owned 1,449,765 shares in the company, valued at approximately $15,831,433.80. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artiva Biotherapeutics Stock Down 3.4%

NASDAQ:ARTV opened at $10.42 on Friday. The firm has a market capitalization of $509.43 million, a P/E ratio of -3.16 and a beta of 2.18. The company has a fifty day moving average of $10.66 and a 200 day moving average of $8.96. Artiva Biotherapeutics, Inc. has a 52 week low of $2.22 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). As a group, analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.

Wall Street Analyst Weigh In

ARTV has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

Hedge funds have recently made changes to their positions in the stock. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics during the 3rd quarter valued at approximately $41,000. State of Wyoming bought a new stake in Artiva Biotherapeutics in the second quarter worth $45,000. Bank of America Corp DE grew its stake in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at $53,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at $58,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.